Celltrion's Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed ...
Chosunbiz1d
Celltrion launches Steqeyma autoimmune treatment in U.S. market
Celltrion launches Steqeyma autoimmune treatment in U.S. market Celltrion unveils its competitive approach for Steqeyma in ...
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and ...
Drug Store News2d
FDA approves Celltrion's Xolair biosimilar
Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...
Korea JoongAng Daily on MSN13h
Celltrion to cancel $140M in treasury shares
Celltrion will cancel treasury shares worth 203.3 billion won ($140 million) to enhance shareholder value, the Korean drugmaker said on Friday.
Yonhap News Agency on MSN1d
Celltrion launches autoimmune disease treatment in U.S.
Steqeyma, a treatment for plaque psoriasis, Crohn's disease, active psoriatic arthritis and ulcerative colitis, is ...
Celltrion launches Stelara biosimilar in US
South Korean biopharmaceutical company Celltrion announced Thursday that it has launched Steqeyma (ustekinumab), a biosimilar treatment for autoimmune diseases, in the US market. Steqeyma, a ...
Morningstar2d
Celltrion's Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada
CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian ...
Contract Pharma4d
FDA Approves Celltrion’s Biosimilar to XOLAIR
The FDA has approved Celltrion’s OMLYCLO (omalizumab-igec) as the first and only biosimilar designated as interchangeable ...
Business Wire2d
Celltrion's Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada
TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry ...
Financial Post2d
Celltrion's Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada
TORONTO — Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry TM starting April 1, ...